⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADAG News
Adagene Inc. American Depositary Shares
Adagene to Participate in Two Upcoming Investor Conferences
globenewswire.com
ADAG
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
globenewswire.com
ADAG
ABBV
BIIB
BMRN
BLRX
CNSP
CYCN
GEN
GILD
GRAF
GSK
HSIC
HUBS
IBIO
INCY
JAZZ
JNJ
MAGN
MARA
MRK
NVS
OMER
PFE
PRGS
REGN
RGNX
SRPT
TENB
TGLS
TGTX
TNDM
TXG
VRTX
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
globenewswire.com
ADAG
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
globenewswire.com
ADAG
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
globenewswire.com
ADAG
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
globenewswire.com
ADAG
INCY
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
globenewswire.com
ADAG
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
ADAG
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
globenewswire.com
ADAG
Adagene to Participate in Two Upcoming Investor Conferences
globenewswire.com
ADAG